EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis

Ayalew Tefferi iD, Saubia Fathima, Ali Khalid A Alsugair, Fnu Aperna, Anuya Natu iD, Maymona G Abdelmagid, Clifford M Csizmar, Mark Gurney, Terra L Lasho, Christy M Finke, Abhishek A Mangaonkar iD, Aref Al-Kali iD und 5 weitere

American Journal of Hematology · 2024-12 · 99 (12) · 2321-2327

DOI: 10.1002/ajh.27492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 27.09.2024. Verfasst von Ayalew Tefferi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Mutation, Leukemia, Myelomonocytic, Chronic, Repressor Proteins, Phenotype. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The current study was inspired by observations from exploratory analyses of an institutional cohort with chronic myelomonocytic leukemia (CMML; N = 398) that revealed no instances of blast transformation in the seven patients with plant homeodomain finger protein 6 ( PHF6 ) mutation ( PHF6 MUT ). A subsequent Mayo Clinic enterprise‐wide database search identified 28 more cases with PHF6 MUT . Compared with their wild‐type PHF6 counterparts ( PHF6 WT ; N = 391), PHF6 MUT cases ( N = 35) were more likely to co‐express TET2 (89% vs. 45%; p < .01), RUNX1 (29% vs. 14%; p = .03), CBL (14% vs. 2%; p < .01), and U2AF1 (17% vs. 6%; p = .04) and less likely SRSF2 (23% vs. 45%; p < .01) mutation. They were also more likely to display loss of Y chromosome (LoY; 21% vs. 2%; p < .01) and platelets

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutationLeukemia, Myelomonocytic, ChronicRepressor ProteinsPhenotypeHumansMaleFemaleMiddle AgedAgedPrognosisAged, 80 and overAdultCore Binding Factor Alpha 2 SubunitDNA Methyltransferase 3ADNA-Binding ProteinsDNA (Cytosine-5-)-MethyltransferasesDioxygenasesProto-Oncogene ProteinsSplicing Factor U2AFSerine-Arginine Splicing Factors

Substanzen

PHF6 protein, humanRepressor ProteinsDNMT3A protein, humanCore Binding Factor Alpha 2 SubunitDNA Methyltransferase 3ADNA-Binding ProteinsRUNX1 protein, humanDNA (Cytosine-5-)-MethyltransferasesDioxygenasesProto-Oncogene Proteins

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Ayalew Tefferi, Anuya Natu, Abhishek A Mangaonkar, Aref Al-Kali, Animesh Pardanani, Rong He, Naseema Gangat, Mrinal M Patnaik

Zitieren

APA

Tefferi, A., Fathima, S., Alsugair, A. K. A., Aperna, F., Natu, A., Abdelmagid, M. G., Csizmar, C. M., Gurney, M., Lasho, T. L., Finke, C. M., Mangaonkar, A. A., Al-Kali, A., Pardanani, A., Reichard, K. K., He, R., Gangat, N., & Patnaik, M. M. (2024). PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis. American Journal of Hematology, 99(12), 2321-2327. https://doi.org/10.1002/ajh.27492

Vancouver

Tefferi A, Fathima S, Alsugair AKA, Aperna F, Natu A, Abdelmagid MG, et al. PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis. American Journal of Hematology. 2024;99(12):2321-2327. doi:10.1002/ajh.27492

BibTeX
@article{Tefferi2024,
  author = {Tefferi, Ayalew and Fathima, Saubia and Alsugair, Ali Khalid A and Aperna, Fnu and Natu, Anuya and Abdelmagid, Maymona G and Csizmar, Clifford M and Gurney, Mark and Lasho, Terra L and Finke, Christy M and Mangaonkar, Abhishek A and Al-Kali, Aref and Pardanani, Animesh and Reichard, Kaaren K and He, Rong and Gangat, Naseema and Patnaik, Mrinal M},
  title = {PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis},
  journal = {American Journal of Hematology},
  year = {2024},
  volume = {99},
  number = {12},
  pages = {2321--2327},
  doi = {10.1002/ajh.27492}
}
Kostenlos starten →